Comprehensive Blood Panel: What Yours Misses, and What Is Wasted On It

A patient of forty-seven arrives with a results printout from his health fund (kupat holim). Thirty-two lines, all of them inside the reference range, and the sentence he was given over the phone was that everything was normal. As far as he is concerned, he has had a comprehensive blood panel. In fact the three measurements that could change what is done for him over the next decade — ApoB, Lp(a) and fasting insulin — do not appear on the sheet at all. They did not come back normal. They were simply never measured.

That is the central gap. A broad panel is not necessarily a comprehensive one, and a long panel certainly is not. The one question that justifies adding a marker is whether the result — any result it could produce — changes a decision. That standard cuts both ways: it explains what is missing from the routine panel, and why much of what is sold privately as a comprehensive panel buys nothing but incidental findings.

What makes a comprehensive blood panel genuinely comprehensive

The panel a family physician orders through the health funds was built for a particular job, and it does that job well: detecting common disease cheaply across a large population. Full blood count, basic chemistry, a standard lipid profile, TSH, sometimes vitamin D. The logic behind it is cost-effectiveness at the scale of a million members, not quantifying the twenty-year risk of one asymptomatic forty-five-year-old. Those are two different tasks, and a tool designed for the first should not be expected to perform the second.

A comprehensive assessment is therefore built on three conditions every marker has to meet: it can be measured reliably, there is something to be done about it, and what would be done rests on reasonable evidence. A marker that satisfies all three is worth measuring even if it is not on the routine panel; one that fails any of them does not become useful by appearing on a longer list.

Lipids: the panel everyone has, and the number it does not measure

The standard lipid panel reports total cholesterol, LDL-C, HDL-C and triglycerides. In most laboratories the LDL-C is not measured at all but calculated from a formula, and that calculation becomes less reliable in exactly the two situations where precision matters most — when triglycerides are high, and when LDL is already low on treatment.

The measurement that is missing is ApoB. Every atherogenic particle carries a single ApoB molecule, so measuring it counts particles rather than cholesterol mass. In most people the two numbers agree. In a significant minority — chiefly those with the metabolic profile of high triglycerides and low HDL — the LDL-C reads normal while the particle count is high. What changes clinically: the intensity of treatment and the target. ApoB is not usually part of the routine lipid panel, though the test is available in laboratories in Israel. It is worth asking your health fund or the laboratory what is needed to add it and what the cover is.

Lp(a) is the clearest case of a test worth doing once in a lifetime. Its concentration is almost entirely genetically determined, it does not shift with diet or lifestyle, and roughly a fifth of the population carries an elevated level without knowing it. What changes clinically if it is high: the targets for the other risk factors tighten, and the question of testing first-degree relatives arises. A high Lp(a) is not a verdict — it is a reason to treat everything that can be modified more decisively.

A panel of thirty lines all reported as normal is not a comprehensive test. It is a broad one. Comprehensive is measured by which decisions the result could change, not by how many lines were printed.

Glucose and metabolism: why a normal glucose is not an answer

The routine panel includes fasting glucose, and sometimes HbA1c. Both measure the output of the metabolic system, not the effort it is expending to produce that output. During the compensated phase — which can run a decade or more — the pancreas secretes more and more insulin to hold glucose normal, and glucose duly stays normal. The test is reassuring; the biology no longer is.

Fasting insulin, together with the glucose, allows HOMA-IR to be calculated and this phase to be seen while it is still largely reversible. It is almost always a test you have to request yourself; it is not part of the routine panel. What changes clinically if it is raised: the intensity of lifestyle intervention, the order of priority between resistance training and diet, and sometimes an earlier decision about medication.

HbA1c carries a limitation worth knowing. It measures glycated haemoglobin, so anything that alters the lifespan of the red cell distorts it. Iron deficiency tends to raise it; haemolysis, bleeding and thalassaemia trait — common in some population groups in Israel — tend to lower it. An HbA1c of 5.9 in a woman with a low ferritin is not necessarily what it appears to be.

Inflammation, liver and kidney: three markers that are read wrongly

hs-CRP is not the same test as ordinary CRP. Ordinary CRP was designed to detect acute infection and is too coarse to distinguish between low values; hs-CRP measures accurately in the low range where most of the population sits, and that is where the information is. Its limitation is fundamental: it is not specific — infection, injury, active autoimmune disease and even hard training raise it. A single high value is not enough to draw a conclusion from; repeat it at least two weeks later, when you are well. What changes clinically: a consistently raised hs-CRP moves the cardiovascular risk estimate upward, and in the JUPITER trial it identified a group who benefited from a statin despite an LDL that was not high.

ALT is on every panel already, but its reference range derives from populations a substantial proportion of whom have fatty liver. So a value at the top of the normal band — 38, say — reads as normal in a person with an increased waist circumference, when in fact it is the most readily available sign of metabolic fatty liver disease (MASLD). What changes clinically: a consistently raised ALT justifies assessment for fibrosis. The FIB-4 index is calculated from age, AST, ALT and platelet count — figures already on the sheet in your hand, with no further test.

Creatinine and eGFR are the standard measures of kidney function, and they too are indirect: creatinine derives from muscle mass. A very muscular person appears to have worse kidney function than he really does, and a sarcopenic person can look normal while function has fallen. When the picture does not hang together, cystatin C gives an estimate independent of muscle mass. One further test deserves a place here, although it is not a blood test and is not usually ordered: the urine albumin-to-creatinine ratio, which signals early kidney damage and cardiovascular risk years before the eGFR moves.

Thyroid and hormones

TSH is on almost every panel, and in most cases it is enough as a first test. When it falls outside the range, the next step is free T4 and TPO antibodies — the first establishes whether there is genuine hypothyroidism, the second whether the cause is autoimmune. Subclinical hypothyroidism, meaning a mildly raised TSH with a normal free T4, is very common and does not require treatment in most people.

The hormone panel is the part most easily ordered wrongly. Testosterone is measured in the morning and fasting, and a single low result is not a diagnosis — it is a reason to repeat the test, add SHBG and calculate the free fraction, and check LH and FSH to establish whether the source is testicular or pituitary. In women, timing within the cycle changes the interpretation entirely, and the diagnosis of menopause is clinical rather than laboratory. The simple rule is that a hormone marker is measured when there is a clinical question it answers, not to fill a column.

Vitamins and minerals

Vitamin D — deficiency is common in Israel despite the sun, particularly among people who work indoors, among older adults, and among women whose clothing covers most of the body. Correcting a genuine deficiency is sensible and safe. The honest qualification: large randomised trials have not shown that supplementing vitamin D in adults who are not deficient reduces cardiac events or the incidence of cancer. This is the correction of a deficiency, not a longevity supplement.

B12 — particularly relevant for anyone on metformin or proton pump inhibitors long term, for vegetarians and vegans, and after bariatric surgery. A borderline value is not decisive on its own; MMA or homocysteine clarify whether there is deficiency at the cellular level.

Ferritin — here there are two common errors in opposite directions. A low ferritin with a normal haemoglobin is iron deficiency without anaemia, very common in women of reproductive age and in endurance athletes, and it explains fatigue and declining fitness long before the blood count changes. In the other direction, ferritin is an acute-phase protein — it rises with inflammation, obesity and alcohol intake, so a high value does not necessarily indicate iron overload. It is a consistently high transferrin saturation that warrants investigation for haemochromatosis.

The table below gathers the principal markers. The ranges in it are a framework for a discussion with a physician, not a prescription — the gap between laboratory normal and clinically desirable is what it is trying to show.

More tests are not automatically better

This is the part that is less comfortable to say in a clinic that sells tests. A reference range is generally defined so that about five percent of healthy people fall outside it. On a panel of twenty independent tests, the chance that a perfectly healthy person produces at least one abnormal result therefore sits at around two-thirds. Add another twenty lines and the probability climbs further — and with it investigation, imaging, sometimes a procedure, and a period of real anxiety that is recorded nowhere as a cost.

The sharpest example is tumour markers. CEA, CA 19-9 and CA-125 appear on private panels marketed as comprehensive, and they are not screening tests. They were developed for monitoring known disease, and their false-positive rate in a healthy population is high. In the case of CA-125, a large randomised trial in postmenopausal women did not show a significant reduction in mortality from ovarian cancer. PSA is a different story — it has a place, but as a shared and informed decision, not as a line that crept onto a panel.

These are the markers that mostly do not justify their place on the panel of a person without symptoms:

• Tumour markers as screening — CEA, CA 19-9, CA-125 — other than for monitoring known disease or a hereditary syndrome
• Broad IgG-based food sensitivity panels, which have no diagnostic basis
• Serum magnesium as a measure of magnesium stores in the body
• Free T3 and reverse T3 in a person with no known thyroid disease
• Vitamin D repeated every three months in someone already within range
• Any marker for which you cannot say in advance what you would do if it came back high and what you would do if it came back low

What to ask for, and how to read what comes back

Most of the value is in the boring details of execution, not in the list of tests:

• Add the three that are missing. ApoB, Lp(a) once in a lifetime, and fasting insulin. These give the highest return relative to effort and cost in most adults.
• Check what is covered before you pay. Cover varies between health funds, and between basic cover and supplementary insurance (bituach mashlim), and sometimes depends on the indication the physician records. Worth asking, and worth not assuming either way.
• Get the conditions of the test right. Ten to twelve hours of fasting for glucose, insulin and triglycerides; testosterone in the morning; no hs-CRP during an acute illness or within two days of hard training.
• Repeat an abnormal result before acting on it. Biological and analytical variation are real, and a considerable share of isolated abnormal values return to normal on a second test.
• Follow the trend, not the point. An ALT that has moved from 19 to 33 over three years says more than a single ALT of 33, even though both are within range.

And three questions worth the time, every time a panel is offered to you: what would you do differently if the result came back high, what would you do differently if it came back low, and what happens if it comes back borderline. If the answer is the same in all three cases, the test is not adding information — it is adding a line. A good comprehensive blood panel is not the longest one. It is the one in which every line was chosen because somebody knew in advance what they would do with the answer.